How is METex14-related NSCLC treated? FDA takes positive view of MET inhibitor Tabrecta

Novartis Pharmaceuticals said recently that the FDA has accelerated approval of tabrecta (capmatinib) applications to treat adult patients with metastatic non-small cell lung cancer (NSCLC), whose mutations in tumors cause MET's 14exetic jump (METex14)The FDA's decision is based on the latest results of a critical, non-randomized Phase II GEOMETRY mono-1 clinical trial that evaluated 97 patients with advanced or metastatic NSCLC with advanced or metastatic NSCLC who received Tabrecta (capmatinib) twice a dayThe results showed that the overall remission rate (ORR) was 68% in patients who had not been treated before, and the duration of the reaction was 12.6 months, while the overall remission rate (ORR) of patients who had previously received treatment was 41% and the duration of the reaction was 9.7 monthsCommon treatment-related adverse reactions are edema, nausea, fatigue, vomiting, difficulty breathing, and decreased appetiteAt present, non-small cell lung cancer (NSCLC) is still one of the highest mortality malignant tumors in human beings and has become a social problem that seriously threatens people's life and health